



## Mirum Pharmaceuticals to Participate at Four Upcoming Conferences

February 18, 2020

FOSTER CITY, Calif.--(BUSINESS WIRE)--Feb. 18, 2020-- Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM), a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases, today announced that company management will participate at the following conferences in February and March.

- SVB Leerink 9<sup>th</sup> Annual Global Healthcare Conference
  - Location: New York, NY
  - Presentation date: Wednesday February 26, 2020
  - Presentation time: 9:30 a.m. ET
- Cowen 40<sup>th</sup> Annual Healthcare Conference
  - Location: Boston, MA
  - Presentation date: Monday March 2, 2020
  - Presentation time: 2:10 p.m. ET
- Raymond James 41<sup>st</sup> Annual Institutional Investors Conference
  - Location: Orlando, FL
  - Presentation date: Wednesday March 4, 2020
  - Presentation time: 9:15 a.m. ET

A live audio webcast and archive of the presentations outline above will be available at <http://ir.mirumpharma.com>

Additionally, the company will be participating the 32<sup>nd</sup> Annual ROTH Conference, and will be on a panel on Monday March 16 at 11:00 a.m. discussing Orphan Therapeutics.

### About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company's lead product candidate, maralixibat, is an investigational oral drug in development for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC). For more information, visit [MirumPharma.com](http://MirumPharma.com). Follow Mirum on [Twitter](#), [Facebook](#) and [LinkedIn](#).

View source version on businesswire.com: <https://www.businesswire.com/news/home/20200218005870/en/>

Source: Mirum Pharmaceuticals, Inc.

### Media Contact:

Heidi Chokeir, Ph.D.  
Canale Communications  
619-203-5391  
[heidi@canalecomm.com](mailto:heidi@canalecomm.com)

### Investor Contact:

Ian Clements, Ph.D.  
650-667-4085  
[ir@mirumpharma.com](mailto:ir@mirumpharma.com)